CONNECT WITH US
HealthTech

HealthTech

Custom MRI tool could show within weeks if pancreatic cancer treatment is working

Medical Xpress logo

Published on

Add as a preferred source on Google
Custom MRI tool could show within weeks if pancreatic cancer treatment is working

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

About 60% of people diagnosed with pancreatic cancer don't qualify for surgery because their disease is too advanced. For these patients, treatment typically begins with chemotherapy, in the hope that the tumor will shrink enough to be surgically removed, which offers the best chance of long-term survival. A new clinical trial at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) is testing a custom imaging tool designed to measure much earlier whether that chemotherapy is working, so treatment can change quickly if it is not.

The trial will test dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with standard clinical evaluation in patients with pancreatic ductal adenocarcinoma that involves arteries or veins near the pancreas but can be removed with the right treatment beforehand. DCE-MRI measures blood perfusion in the tumor, which can show disease status.

The study will enroll 50 participants and is led by Shafia Rahman, M.D., a medical oncologist at the OSUCCC—James. The tool was developed at the OSUCCC—James in partnership with Harrison Kim, Ph.D., a radiology scientist and director of the Quantitative Medical Imaging Laboratory.

"Unfortunately, the tools we have right now (CT scans) cannot give us information about how well the treatment is working to kill cancer cells earlier in the disease treatment process. This really matters in advanced pancreatic cancer because patients often experience muscle wasting and weight loss that make tolerating sustained treatment challenging," said Rahman.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.